Redemption Time Redemption Time
Okay time for Management to step up here.
Last weekend Peptide Pete took the time to post all the material milestones that Arch has accomplished over the past few years.
The accomplishments are both impressive and material.
We all agree that our current market cap is extremely undervalued for what we have accomplished. We have been under siege from a group of Algorithmic short sellers for the past two years. The reason these short sellers have been successful is due to the lack of buyers.
Management has accomplished great things and we are in the middle of a phase 2 AKI trial with a new Pontiac Phase 2 trial on our re-purposed drug Cilastatin scheduled to commence in late 2024.
I personally feel the lack of buyers is a result of lack of awareness. Management needs to step up here and start pounding the pavement and promote the science, promote the accomplishments and promote the opportunity here.
Our share price should be at $8 currently not $1.50.